Cyclophosphamide‐induced ovarian failure and its therapeutic significance in patients with breast cancer

The effect of cyclophosphamide (CY) on ovarian function was studied in patients with breast cancer receiving prolonged daily administration of this agent (100 mg/day) after radical surgery. Out of 18 premenopausal patients that received 8.4–39.9 g CY, 15 developed permanent amenorrhea. The average dose given before the onset of amenorrhea was 5.2 g in patients in their 40s and 9.3 g in their 30s. Urinary estrogens and serum progesterone were measured weekly for approximately 6 months postoperatively in six patients receiving CY. After the onset of amenorrhea, the levels of both hormones ceased to show their normal cyclic changes and remained low persistently, meanwhile serum FSH and LH were markedly elevated. No ovarian follicle was histologically found in three amenorrheic patients who underwent therapeutic oopho‐rectomy after CY therapy. These findings indicate that CY induced primary ovarian failure.

[1]  C. Ruckley,et al.  A 5 year follow up of lords dilation for hemorrhoids , 1976 .

[2]  N. Wolmark,et al.  Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. , 1975, Surgery, gynecology & obstetrics.

[3]  C. Redmond,et al.  1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. , 1975, The New England journal of medicine.

[4]  T. Barratt,et al.  CYCLOPHOSPHAMIDE TREATMENT IN STEROID-SENSITIVE NEPHROTIC SYNDROME OF CHILDHOOD , 1975, The Lancet.

[5]  G. Sharpe.  Letter: Indomethacin and closure of the ductus arteriosus. , 1975, Lancet.

[6]  A. Murphy,et al.  Long-term assessment of cyclophosphamide therapy for nephrosis in children. , 1974, Lancet.

[7]  F. Martin,et al.  Cyclophosphamide-induced ovarian failure. , 1973, The New England journal of medicine.

[8]  S. Carter.  Single and combination nonhormonal chemotherapy in breast cancer , 1972, Cancer.

[9]  J. Biggart,et al.  Cyclophosphamide and reproductive function. , 1972, Lancet.

[10]  P. Uldall,et al.  Sterility and cyclophosphamide. , 1972, Lancet.

[11]  K. Fairley,et al.  Sterility and testicular atrophy related to cyclophosphamide therapy. , 1972, Lancet.

[12]  J. Miller,et al.  Multiple late complications of therapy with cyclophosphamide, including ovarian destruction. , 1971, The American journal of medicine.

[13]  J. Cogswell.  Asplastic anaemia and infectious hepatitis. , 1970, Lancet.

[14]  M. Shearn,et al.  Virus-like structure in Sjögren's syndrome. , 1970, Lancet.

[15]  G. Ross,et al.  Radioimmunoassay for human follicle-stimulating hormone: physiological studies. , 1968, The Journal of clinical investigation.

[16]  R K Ausman,et al.  Surgical Adjuvant Chemotherapy in Cancer of the Breast: Results of a Decade of Cooperative Investigation , 1968, Annals of surgery.

[17]  W. M. Fosdick,et al.  Long-term cyclophosphamide therapy in rheumatoid arthritis. , 1968, Arthritis and rheumatism.

[18]  A. R. Midgley,et al.  Radioimmunoassay for Human Follicle-Stimulating Hormone1 , 1967 .

[19]  P. Leymarie,et al.  A study of estrogen fluorescence using Ittrich's procedure. , 1966, Acta endocrinologica.

[20]  J B BROWN,et al.  A chemical method for the determination of oestriol, oestrone and oestradiol in human urine. , 1955, The Biochemical journal.